(Q38884170)

English

Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention (English)

1 reference

Europe PubMed Central

7 September 2017

1 reference

based on heuristic

inferred from title

Kristel Van Laethem

4

object named as

Kristel Van Laethem

0 references

5

object named as

Jan Balzarini

1 reference

Europe PubMed Central

7 September 2017

author name string

Joeri Auwerx

1

1 reference

Europe PubMed Central

7 September 2017

Katrien O François

2

1 reference

Europe PubMed Central

7 September 2017

Kris Covens

3

1 reference

Europe PubMed Central

7 September 2017

language of work or name

0 references

publication date

19 October 2008

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

382

1 reference

Europe PubMed Central

7 September 2017

1

1 reference

Europe PubMed Central

7 September 2017

10-19

1 reference

Europe PubMed Central

7 September 2017

Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Carbohydrate-binding Agents Cause Deletions of Highly Conserved Glycosylation Sites in HIV GP120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Inhibition of HIV entry by carbohydrate-binding proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Pradimicin A, a carbohydrate-binding nonpeptidic lead compound for treatment of infections with viruses with highly glycosylated envelopes, such as human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Proteins that bind high-mannose sugars of the HIV envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Structure of a V3-containing HIV-1 gp120 core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

The Urtica dioica Agglutinin Is a Complex Mixture of Isolectins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.09.010

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2008.09.010

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38884170&oldid=2033534598"